0000000000018279

AUTHOR

Nana Scotto

showing 3 related works from this author

Phase II Study of Bevacizumab in Combination with Trastuzumab and Capecitabine as First-Line Treatment for HER-2-positive Locally Recurrent or Metast…

2012

Abstract We report the first results from a phase II, open-label study designed to evaluate the efficacy and safety of bevacizumab in combination with trastuzumab and capecitabine as first-line therapy for human epidermal growth factor receptor (HER)-2-positive locally recurrent (LR) or metastatic breast cancer (MBC). Patients were aged ≥18 years with confirmed breast adenocarcinoma, measurable LR/MBC and documented HER-2-positive disease. Patients received bevacizumab (15 mg/kg on day 1) plus trastuzumab (8 mg/kg on day 1 of cycle 1, 6 mg/kg on day 1 of each subsequent cycle) plus capecitabine (1,000 mg/m2 twice daily, days 1–14) every 3 weeks until disease progression, unacceptable toxici…

AdultMaleOncologyCancer Researchmedicine.medical_specialtyBevacizumabReceptor ErbB-2HER-2-positivePhases of clinical researchBreast NeoplasmsAntibodies Monoclonal HumanizedDeoxycytidineDisease-Free SurvivalBreast Neoplasms MaleCapecitabineAcademia-Pharma IntersectTrastuzumabInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointHumansNeoplasm MetastasisAdverse effectskin and connective tissue diseasesCapecitabineAgedAged 80 and overbusiness.industryFirst-lineMiddle AgedTrastuzumabmedicine.diseaseMetastatic breast cancerMetastatic breast cancerBevacizumabOncologyFluorouracilFemaleFluorouracilNeoplasm Recurrence Localbusinessmedicine.drug
researchProduct

Exploratory outcome analyses according to stage and residual disease in the ICON7 trial of front-line carboplatin/paclitaxel (CP) ± bevacizumab (BEV)…

2015

5548 Background: In ICON7, progression-free survival (PFS) was significantly improved in patients (pts) receiving BEV with front-line CP and continued as a single agent [Perren 2011] but no overall...

OncologyCancer Researchmedicine.medical_specialtyBevacizumabbusiness.industrydigestive oral and skin physiologyFront lineDiseasemedicine.diseaseCarboplatin/paclitaxelSurgeryOncologyInternal medicineMedicineSingle agentIn patientStage (cooking)businessOvarian cancermedicine.drugJournal of Clinical Oncology
researchProduct

Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab …

2018

Objective In the randomized phase 3 ICON7 trial (ISRCTN91273375), adding bevacizumab to chemotherapy for newly diagnosed ovarian cancer significantly improved progression-free survival (PFS; primary endpoint) but not overall survival (OS; secondary endpoint) in the intent-to-treat (ITT) population. We explored treatment effect according to stage and extent of residual disease. Methods Patients with stage IIB–IV or high-risk (grade 3/clear-cell) stage I–IIA ovarian cancer were randomized to receive six cycles of carboplatin and paclitaxel either alone or with bevacizumab 7.5 mg/kg every 3 weeks followed by single-agent bevacizumab for 12 further cycles (total duration 12 months). Post hoc ex…

0301 basic medicineOncologymedicine.medical_specialtyNeoplasm ResidualPaclitaxelBevacizumabmedicine.medical_treatmentPopulationArticleCarboplatin03 medical and health scienceschemistry.chemical_compound0302 clinical medicineOvarian cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointHumansCytoreductive surgeryStage (cooking)educationNeoplasm StagingOvarian NeoplasmsChemotherapyeducation.field_of_studybusiness.industryHazard ratioObstetrics and GynecologyResidual diseasemedicine.diseaseCarboplatinBevacizumab030104 developmental biologyOncologychemistry030220 oncology & carcinogenesisFemaleOvarian cancerbusinessmedicine.drug:Ciencias de la Salud::Oncología [Materias Investigacion]
researchProduct